This is a resubmission for The University of Puerto Rico Comprehensive Cancer Center (UPRCCC) and The University of Texas M. D. Anderson Cancer Center (MDACC) Partnership for Excellence in Research Grant, which addresses comments and recommendations from the 1) summary statement, 2) NCI Site Visit, and 3) IAC and PSC Committees. Areas strengthened in this application include: leadership, communication, committee oversight, evaluation, career development and mentorship. Funds granted in this award will be used to: 1) support 3 full projects in cancer biology and prevention and 1 pilot project in epidemiology, 2) enhance existing collaborations and establish new collaborations, 3) increase faculty/trainee participation in the training program, 4) expand efforts in our Outreach Program to impact a larger audience, and 5) fortify and stabilize the infrastructure developing at the UPRCCC. Research grants included target 1) developing new cancer imaging techniques, 2) regulating RNA in eukaryotic cells, 3) reducing cancer risk through combined alcohol and tobacco treatment and 4) assessing the role of insulin resistance syndrome as a risk factor for endometrial cancer. The Outreach Program, which was added into the original grant mid-year 3, has been expanded to include cancer related to tobacco, as well as breast, cervical and HPV. The Training Program has also been expanded in scope to impact more faculty and trainees through a comprehensive career development and mentorship training program. The original grant (2002) was awarded to establish a comprehensive long-term mutually beneficial relationship to target and eradicate cancer health disparities. The two short term objectives of the original application were met: 1) develop independent cancer research investigators and 2) establish a strong working relationship based on mutual benefit, identified strengths and reciprocity. The 3rd long-term objective of the Partnership is to regain NCI-designation for the UPRCCC. Thus far, the Partnership has set the foundation for a dynamic collaboration dedicated to enhancing each partner's strengths and eliminating each partner's weaknesses. The Partnership has also served as the catalyst for two major laws passed in Puerto Rico, one of which resulted in the allocation of funding for establishing the infrastructure and recruiting top notch faculty to the UPRCCC. As of 2008, the Partnership is far from reaching its long-range goal of regaining NCI-designation for the UPRCCC. Funding for the U54 resubmission is critical to maintain the momentum of the Partnership's joint efforts in Cancer Research, Training and Outreach.

Public Health Relevance

This resubmission seeks to foster and support an existing collaboration between the UPRCCC and MDACC. By addressing the differences in incidence, prevalence, mortality, and burden of cancer that exist among Hispanic populations in the US, the Partnership will strive to reduce these differences through efforts in Research, Outreach, and Training. Partnership contributions will also aid in building a stronger national cancer program through the development of a pipeline of well-trained, Hispanic cancer researchers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-K (O1))
Program Officer
Ogunbiyi, Peter
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
Internal Medicine/Medicine
Other Domestic Higher Education
United States
Zip Code
Bottsford-Miller, Justin; Choi, Hyun-Jin; Dalton, Heather J et al. (2015) Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clin Cancer Res 21:602-10
Previs, Rebecca A; Coleman, Robert L; Harris, Adrian L et al. (2015) Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res 21:955-61
Cho, Min Soon; Vasquez, Hernan G; Rupaimoole, Rajesha et al. (2014) Autocrine effects of tumor-derived complement. Cell Rep 6:1085-95
Wu, Sherry Y; Lopez-Berestein, Gabriel; Calin, George A et al. (2014) RNAi therapies: drugging the undruggable. Sci Transl Med 6:240ps7
Alvarez-Berríos, Merlis P; Castillo, Amalchi; Rinaldi, Carlos et al. (2014) Magnetic fluid hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell lines. Int J Nanomedicine 9:145-53
Huang, Xuelin; Ning, Jing; Wahed, Abdus S (2014) Optimization of individualized dynamic treatment regimes for recurrent diseases. Stat Med 33:2363-78
Ortiz, Ana Patricia; Pérez-Irizarry, Javier; Soto-Salgado, Marievelisse et al. (2014) Human papillomavirus-related cancers among people living with AIDS in Puerto Rico. Prev Chronic Dis 11:E80
Quintás-Cardama, Alfonso; Choi, Sangbum; Kantarjian, Hagop et al. (2014) Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma Leuk 14:327-334.e8
Pradeep, Sunila; Kim, Seung W; Wu, Sherry Y et al. (2014) Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 26:77-91
Tucker, Susan L; Gharpure, Kshipra; Herbrich, Shelley M et al. (2014) Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res 20:3280-8

Showing the most recent 10 out of 41 publications